Bioxytran Inc (BIXT)

[Ecomike]

Well that is great news, I will check it later. Any highlights?

$BIXT is getting steady love and affection, volume picking up too

[Retire43]

We are starting the week higher!

[Retire43]

BIXT files 2nd quarterly 10Q!

[Ecomike]

Seems to be some mini-whaling going on here this week as the $BIXT share price rises.

I feel a disturbance in the force..

[Ecomike]

Yes, Plus the possible research on Monkey pox.

[Retire43]

Now with OTCQB Certification filed, I’m wondering how long that will take to grant?

Greater than 280,000 shares traded yesterday! Maybe that was on the potential of the OtcQB status about to happen ?

[i_like_bb_stock]

Yes

[Ecomike]

Where there is smoke there is fire. $BIXT is smoking now.

OTC QB applied for.

[Ecomike]

$BIXT find on LinkedIn folks.

This could real interesting, real fast here. Add in OTC QB application filed, and readable on OTC Markets. Like pouring gas on a fire..

[Retire43]

Otc market.com

8/8/22 OTCQB Certification

Filing

< 111.5M shares

[Retire43]

This is great news!

Those warrants would have diluted the OS of the company if exercised!

Now they are canceled!

BIXT could have a huge run here!

[Ecomike]

SEC nailed some bad con debt folks in NY, news came out a day ago, and the bad folks must return all the shares, cancel all the debt, cancel all the warrants of all the OTC stocks they were milking.

They had BIXT warrants, which if they were under the current retail are now not only dead, but no longer holding us back. Official company news could be leased by all the companies, including BIXT.

https://www.sec.gov/news/press-release/2022-135

[Retire43]

I’ve been accumulating this stock since October 2019!

[Retire43]

5/2
5/9
6/6
5/13
5/20
577
nhibit..
pister
BIXT
Ex
CSTI
GTSM
INTL
PUMA
NITE
TEEN
BIOXYTRAN INC COM
Bid
43000
42000
40200
40200
40000
BS
3.000
140.000( look at this)
2,500
À500
3.000
TAnn
718
7/25
T
"' QQT Drawing set: Default
- O0405
43435
Level Il
E3
OTOX
GTEM
INTL
CSTI
NITE
Ask
43990
44000
47900
50000
50000
AS
2,500
2.500
2.500
2.500
2.500
ann

[Retire43]

Look at the bid!

[Retire43]

GALT gets $60M!
If BIXT would get $60 million We will be $1 billion company in a year!

PS: look at history of GALT

[Retire43]

Looking at company website Dr. Platt has had a number of successful companies and Innovative new drugs!

[i_like_bb_stock]

agreed

[Ecomike]

$BIXT heading back up today. Just needs eyes. Any volume and this beast rockets to $ land in 1-2 days. Will not take much volume either..

[i_like_bb_stock]

easier to get in India for sure

[Ecomike]

Found what I was missing. There was a trial, in India. Next step FDA?

https://www.walshmedicalmedia.com/open-access/galectin-antagonist-use-in-mild-cases-of-sarscov2-pilot-feasibility-randomised-open-label-controlled-trial-61087.html

[Ecomike]

"About ProLectin-M:

ProLectin-M is an orally administered experimental new drug candidate that targets the Carbohydrate Binding Domain portion on the SARS-CoV-2, coronavirus. ProLectin-M is expected to interfere with the binding of the virus to the cell and thereby prevent viral entry into cells.

Preclinical in-vitro and in-vivo preliminary data shows that ProLectin-M is non-toxic for humans. ProLectin-M was used in an open label, randomized, controlled clinical feasibility study in COVID-19 patients with mild-to-moderate COVID-19 disease".

Does this mean they are already going to file for an FDA EUA authorization?

Or still need further trials in a phase III?

That is the first I had seen the claim of the feasibility study...already being done. That is huge, but what is next?

[Ecomike]

Pretty awesome news folks. We are waiting to find out FDA time lines, but my gut (and understanding of the bio-chemistry) says this could be the next Moderna blow out in 1-2 years. All depends on the trial timelines, and Covid19 variants. But BA 5 Covid19 is already as contagious as the measles and CDC/FDA and folks on the hot seat will be funding all sorts of opportunities and helping to get new solutions rushed to market (Limited delays, using the EUA trial process, that cuts 5-10 years off of trials...)

I called the rally on Moderna in March 2020. And Moderna rallied 10X higher than even I expected. And Moderna had hundred of millions of looses, trading on the big boards...

Omicron has out maneuvered the vaccines and adapted over time. And Antivirals like Pfizer's Paxlovid are getting their turn, but if BIXT's stuff works in 3 days with out a rebound, that will be huge.

We still need and FDA EUA trial, and they take time. But even now, IMO, this looks undervalued, 100 to 200% undervalued already even at this stage.

https://sciencescholar.us/journal/index.php/ijhs/article/view/10033

https://www.nejm.org/doi/full/10.1056/NEJMc2206576

Six months after the initial two BNT162b2 immunizations, the median neutralizing antibody pseudovirus titer was 124 against WA1/2020 but less than 20 against all the tested omicron subvariants (Figure 1B). Two weeks after administration of the booster dose, the median neutralizing antibody titer increased substantially, to 5783 against the WA1/2020 isolate, 900 against the BA.1 subvariant, 829 against the BA.2 subvariant, 410 against the BA.2.12.1 subvariant, and 275 against the BA.4 or BA.5 subvariant.

These data show that as compared with the response against the WA1/2020 isolate, the neutralizing antibody titer was lower by a factor of 6.4 against BA.1, by a factor of 7.0 against BA.2, by a factor of 14.1 against BA.2.12.1, and by a factor of 21.0 against BA.4 or BA.5.

In addition, as compared with the median neutralizing antibody titer against the BA.1 subvariant, the median titer was lower by a factor of 2.2 against the BA.2.12.1 subvariant and by a factor of 3.3 against the BA.4 or BA.5 subvariant.
Conclusion, Omicron BA 4 and 5 are winning. and are just as contageous as the measles
*
Among the participants with a history of Covid-19, the median neutralizing antibody titer was 11,050 against the WA1/2020 isolate, 1740 against the BA.1 subvariant, 1910 against the BA.2 subvariant, 1150 against the BA.2.12.1 subvariant, and 590 against the BA.4 or BA.5 subvariant

(even natural immunity from prior infections is not high enough for BA 5)
*
These data show that the BA.2.12.1, BA.4, and BA.5 subvariants substantially escape neutralizing antibodies induced by both vaccination and infection. Moreover, neutralizing antibody titers against the BA.4 or BA.5 subvariant and (to a lesser extent) against the BA.2.12.1 subvariant were lower than titers against the BA.1 and BA.2 subvariants, which suggests that the SARS-CoV-2 omicron variant has continued to evolve with increasing neutralization escape. These findings provide immunologic context for the current surges caused by the BA.2.12.1, BA.4, and BA.5 subvariants in populations with high frequencies of vaccination and BA.1 or BA.2 infection.

[Ecomike]

Pretty awesome news folks. We are waiting to find out FDA time lines, but my gut (and understanding of the bio-chemistry) says this could be the next Moderna blow out in 1-2 years. All depends on the trial timelines, and Covid19 variants. But BA 5 Covid19 is already as contagious as the measles and CDC/FDA and folks on the hot seat will be funding all sorts of opportunities and helping to get new solutions rushed to market (Limited delays, using the EUA trial process, that cuts 5-10 years off of trials...)

I called the rally on Moderna in March 2020.

https://sciencescholar.us/journal/index.php/ijhs/article/view/10033

https://www.nejm.org/doi/full/10.1056/NEJMc2206576

Six months after the initial two BNT162b2 immunizations, the median neutralizing antibody pseudovirus titer was 124 against WA1/2020 but less than 20 against all the tested omicron subvariants (Figure 1B). Two weeks after administration of the booster dose, the median neutralizing antibody titer increased substantially, to 5783 against the WA1/2020 isolate, 900 against the BA.1 subvariant, 829 against the BA.2 subvariant, 410 against the BA.2.12.1 subvariant, and 275 against the BA.4 or BA.5 subvariant.

These data show that as compared with the response against the WA1/2020 isolate, the neutralizing antibody titer was lower by a factor of 6.4 against BA.1, by a factor of 7.0 against BA.2, by a factor of 14.1 against BA.2.12.1, and by a factor of 21.0 against BA.4 or BA.5. In addition, as compared with the median neutralizing antibody titer against the BA.1 subvariant, the median titer was lower by a factor of 2.2 against the BA.2.12.1 subvariant and by a factor of 3.3 against the BA.4 or BA.5 subvariant.
Conclusion, Omicron BA 4 and 5 are winning. and are just as contageous as the measles
*
Among the participants with a history of Covid-19, the median neutralizing antibody titer was 11,050 against the WA1/2020 isolate, 1740 against the BA.1 subvariant, 1910 against the BA.2 subvariant, 1150 against the BA.2.12.1 subvariant, and 590 against the BA.4 or BA.5 subvariant
*
These data show that the BA.2.12.1, BA.4, and BA.5 subvariants substantially escape neutralizing antibodies induced by both vaccination and infection. Moreover, neutralizing antibody titers against the BA.4 or BA.5 subvariant and (to a lesser extent) against the BA.2.12.1 subvariant were lower than titers against the BA.1 and BA.2 subvariants, which suggests that the SARS-CoV-2 omicron variant has continued to evolve with increasing neutralization escape. These findings provide immunologic context for the current surges caused by the BA.2.12.1, BA.4, and BA.5 subvariants in populations with high frequencies of vaccination and BA.1 or BA.2 infection.

[i_like_bb_stock]

big news Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus
https://www.otcmarkets.com/stock/BIXT/news/story?e&id=2279828

[Retire43]

ProLectin-M, a new class of oral antiviral drug

BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral causing diseases announced today that the journal of International Journal of Health Sciences1 released a peer-reviewed article, “Carbohydrate ProLectin-M, a Galectin-3 Antagonist, Blocks SARS-CoV-2 Activity”, that supports ProLectin-M’s in vitro Mode of Action and the initial clinical data results reported in a previous article, referred to below. ProLectin-M is the Company’s leading drug molecule in its pipeline to treat viral infections.
The journal article begins to outline and further define the mechanism of action (MOA) behind the oral galectin inhibitor Prolectin-M. The article confirms and further expands on the preliminary clinical data results from Bioxytran’s first peer-reviewed journal article in the Journal of Vaccines & Vaccination2, “Galectin Antagonist use in Mild Cases of SARS-CoV-2: Pilot Feasibility Randomised, Open Label, Controlled Trial”, whereby human clinical trial results showed elimination of viral load to undetectable levels within a few days. The analytical tests within the scope of this most recent journal article utilize some of the most rigorously binding tests between a Lectin class of protein and carbohydrates.
1) https://sciencescholar.us/journal/index.php/ijhs/article/view/10033
2) https://www.walshmedicalmedia.com/open-access/galectin-antagonist-use-in-mild-cases-of-sarscov2-pilot-feasibility-randomised-open-label-controlled-trial-61087.html
About Bioxytran, Inc.

Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases and bind to the conserved region of the spike protein commonly known as the galectin fold. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
About Galectins

Galectins are carbohydrate-binding proteins that are involved in many physiological functions, such as inflammation, immune responses, cell migration, autophagy, and signaling. They are also linked to diseases such as fibrosis, cancer and heart disease.
About Lectins

Galectins are a class of specific lectins. Lectins are a special class of proteins widely distributed in nature, which selectively recognize and reversibly bind to carbohydrates and glycoconjugates through their binding sites. These proteins, which can be detected through hemagglutination assays, interact with different carbohydrates present in cell and viral surfaces.
About ProLectin-M

ProLectin-M is an orally administered experimental new drug candidate that targets the Carbohydrate Binding Domain portion on the SARS-CoV-2, coronavirus. ProLectin-M is expected to interfere with the binding of the virus to the cell and thereby prevent viral entry into cells. Preclinical in-vitro and in-vivo preliminary data shows that ProLectin-M is non-toxic for humans. ProLectin-M was used in an open label, randomized, controlled clinical feasibility study in COVID-19 patients with mild-to-moderate COVID-19 disease.
Investor Relations

Michael Sheikh

509-991-0245
[e-mail]
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

[Retire43]

This news is just out this morning!

[Retire43]

New science Glycovirology!

https://t.co/65l7jNM322

[Ecomike]

Quiet stealth accumulation continues at $BIXT

[Ecomike]

That is great news :

Big news:

You can now place an order on line in Schwab online or streetsmartedge platform!

Since we started trading on 6/14 you had to call them on the phone to place an order.

On 6/16 stock hit .58!

[Retire43]

Big news:

You can now place an order on line in Schwab online or streetsmartedge platform!

Since we started trading on 6/14 you had to call them on the phone to place an order.

On 6/16 stock hit .58!

[Retire43]

Yes! I think that is happening!

[threebabiesbusy]

Mike check out va*pr…thoughts?

[Ecomike]

I can always tell when a great stock is being stealth accumulated.

The silence is deafening, and the fish nibble up shares hoping not to awake up the whales....

$BIXT

[Retire43]

Yes. It’s going to be epic

As one by one major viruses start to be taken down world wide!

[Ecomike]

The Ninja Covid19 variant cometh? and $BIXT is plotting its funeral?

I love it, the Next Hollywood clot shot- Andromeda Strain block buster movie

[Retire43]

Look at BIXT : www.bioxytraninc.com

Glycovirology is a totally newly science emerging from this company.

Here comes the scary, end of the world as we know it, get boosted 300 times, trust the science, wear N95 or full hasmat suit NINJA ??variant

[Ecomike]

Up 100% already just this month from the back test low. Testing 50 cents now $BIXT

[$theDDmessiah]

;)

[Retire43]

Huge volume day today with some high percentage gain in stock price!

[Retire43]

This is a new Molecule


https://www.mdpi.com/1422-0067/23/14/7739

[Ecomike]

One sign of great stock is when it rallies as the market crashes. $BIXT getting some love at the ask today

[Ecomike]

I should have bought more on that dip...

[RMacchio]

I was told that most of the selling in BIXT over the past few weeks has been from one investor dumping shares. Their position is probably clearing out this week and we should start to see upward movement.

[Ecomike]

$BIXT is one of the few stocks that is green this morning. All the rest seem to fighting some kind of bug, LOL, bleeding red

[Retire43]

I bought shares at 0.26 today!

[Retire43]

I agree ! In my opinion Anything under .50 is a good buy! I think we are going higher !

Shareholders don’t know it’s trading

No press releases!
No 8K stated trademark name ProLectin and 2 patents!

[Ecomike]

Nets out on the bid time today in BIXT-ville.

This is the time to buy in volume IMO

[Ecomike]

Interesting find on Galectin...

$BIXT nice bounce today

https://www.walshmedicalmedia.com/abstract/galectin-antagonist-use-in-mild-cases-of-sarscov2-pilot-feasibility-randomised-open-label-controlled-trial-61087.html

[Ecomike]

BIXT up 16.9% this stock moves on air... Thin ask above